Rasburicase

拉布立酶

Report date: 2022/10/11 09:39:44

Base Information

Drug NameRasburicase
Drug Alias Name拉布立酶（Sanofi）Urate oxidase (Sanofi)拉布立海Urate oxydase (Sanofi)Rasburicasum (Sanofi) +[14] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionUrate oxidases replacements
TargetsUrate oxidase
Therapy Area/IndicationsHyperuricemiaNutritional and Metabolic DiseasesTumor Lysis Syndrome +[5] 
Global Approved IndicationsHyperuricemia
Approved Indications in ChinaHyperuricemia
Original Approved Country/TerritoryEU
Original Approved Date2001/02/22
Country/TerritoryBelgiumUnited StatesItaly +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofi-Aventis GroupeSanofiSanofi-Synthelabo +[4] 
Inactive CompaniesUniversity Of FloridaThe University Of Texas MD Anderson Cancer CenterNational Institute On Aging (NIA)
Active IndicationsHyperuricemia
Inactive IndicationsNutritional and Metabolic DiseasesTumor Lysis SyndromeLymphoma +[4] 

Other Information

ATC CodeV03AF07
Related LinksWikipediaDrugBankKEGG